Clinical updates, including trial initiations, enrollment status and data readouts and publications: Atara, Bio-Thera, Endevica, Evolus, Glenmark, Humanigen, Hutchmed, Optinose, Pluristem, Rhythm, Sanotize, Vaxcyte, Xortx.
Lenzilumab, Humanigen Inc.’s lead candidate, undershot statistical significance on the primary endpoint in the U.S. NIH-sponsored ACTIV-5/BET-B study of treating hospitalized COVID-19 patients. The Short Hills, N.J.-based company’s stock (NASDAQ:HGEN) crumpled in the wake of the results.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Basilea, Bellus, Byondis, Citius, Cyxone, Dyne, Fresenius, Greenwich, Novartis, Y-mabs.
Legislation that would renew the U.S. FDA’s user fee programs is stuck in process on Capitol Hill, a predicament that seems to resist resolution to date. FDA commissioner Robert Califf said on a July 12 webinar that the FDA “is a decision-making machine” that is reliant on both user fees and congressional appropriations, and that a failure on the part of Congress to act on user fee legislation may force the agency to halt new hires and possibly lay off some FDA staff.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Anthos, Arcutis, Can-Fite, Iterum, Lipocine, Perrigo, Pfizer, SCG.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: ADC, Aquestive, Biomica, Exelixis, Freeline, Genentech, Hansa, Immunocore, Ionis, Macrogenics, Mediwound, Moderna, Novo Nordisk, Pliant, Sanofi, Swedish Orphan, Telix, Tonix.
European regulators and health experts have recommended a second booster dose of mRNA COVID-19 vaccines for people between 60 and 79 years of age and for vulnerable people with medical conditions, as Moderna Inc. filed fresh data from its omicron subvariant-adapted shot.
Clinical updates, including trial initiations, enrollment status and data readouts and publications: Inventiva, Moleculin, Myrtelle, Optinose, Regenxbio.
Regulatory snapshots, including global drug submissions and approvals, clinical trial approvals and other regulatory decisions and designations: Alimera, Horizon, MGC, Puma, Siga.
Biopharma happenings, including deals and partnerships, grants, preclinical data and other news in brief: Aditxt, Emergent, Entasis, F-star, Innoviva, La Jolla, Novavax, Rational, Ridgeback, Sino, Vertex.
RSS
